Publication

Video

Supplements and Featured Publications
Current and Emerging Trends in Chronic Myeloid Leukemia
Volume 1
Issue 1

Dr. Jabbour on the ASCEMBL Data With Asciminib in Chronic-Phase CML

Elias Jabbour, MD, discusses data with asciminib in patients with chronic-phase chronic myeloid leukemia.

Elias Jabbour, MD, a professor of the Department of Leukemia, of the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center, discusses data with asciminib in patients with chronic-phase chronic myeloid leukemia (CML).

One of the agents that has emerged in recent years is asciminib, which is not an adenosine triphosphate binding pocket inhibitor but a myristate pocket binding inhibitor. A phase 1 study has demonstrated efficacy with the agent at different dosing schedules. In the ASCEMBL trial, which was presented during the 2020 ASH Annual Meeting & Exposition, patients who had received at least 2 prior TKIs experienced a statistically significant and clinically meaningful improvement in major molecular response with the agent at 24 weeks. 

Arterial-occlusive events were reported in 3.2% of patients who received asciminib vs 1.3% of those who were given bosutinib. On the investigative arm, this was comprised of myocardial ischemia and coronary artery disease.

Related Videos
Farrukh Awan, MD
Minoo Battiwalla, MD, MS
James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss the role of genomic profiling in secondary acute myeloid leukemia.
James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss the treatment goals in secondary acute myeloid leukemia.
James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss factors for picking intensive chemotherapy vs other regimens in acute myeloid leukemia.
James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss dose intensity and sequencing of CPX-351 in secondary acute myeloid leukemia.
James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss long-term data for CPX-351 in acute myeloid leukemia.
James K. McCloskey, MD, and Harry P. Erba, MD, PhD, discuss factors to help determine intensive chemotherapy fitness in acute myeloid leukemia.
James K. McCloskey, MD, and Harry P. Erba, MD, PhD, discuss the diagnosis and prevalence of secondary acute myeloid leukemia.
Minoo Battiwalla, MD, MS